Topical (Intra-Articular) Tranexamic Acid and Transfusion Rates Following Hip Hemiarthroplasty

Status:	Recruiting
Conditions:	Orthopedic
Therapuetic Areas:	Orthopedics / Podiatry
Healthy:	No
Age Range:	55 - Any
Updated:	1/13/2019
Start Date:	January 2016
End Date:	July 2019
Contact:	Michael B O'Sullivan, M.D.
Email:	osullivan@uchc.edu
Phone:	860-679-4932

This study is a double-blinded placebo-controlled clinical trial evaluating the efficacy of 1
gram of topically applied tranexamic acid vs. saline placebo for the reduction of transfusion
following hip hemiarthroplasty surgery.

Inclusion Criteria:

- Patients undergoing hip hemiarthroplasty surgery for a displaced femoral neck fracture

Exclusion Criteria:

- History of hemophilia, history of deep vein thrombosis, history of pulmonary embolism,
history of thrombophilia, history of chronic renal failure

- Patients with coronary ischemia (active or within the past calendar year), patients
who have suffered a myocardial infarction, undergone percutaneous coronary
intervention, undergone coronary artery bypass grafting, or undergone any
revascularization procedure within the past calendar year

- Patients with active subarachnoid hemorrhage, acquired defective color vision,
patients who sustained a pathologic fracture (fracture through a neoplastic lesion),
or patients who are pregnant

- Patients with a known allergy to tranexamic acid

- Patients taking Warfarin, Dabigatran, Rivaroxaban, Apixaban, and Fresh Frozen Plasma

We found this trial at

sites

University of Connecticut Health Center

263 Farmington Ave
Farmington, Connecticut 06030

(860) 679-2000